ACCESSWIRE
08 Dec 2022, 23:05 GMT+10
LUND, SWEDEN / ACCESSWIRE / December 8, 2022 / BioInvent International AB ('BioInvent') (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today provides an update on its clinical and pre-clinical pipeline, including an update on its lead drug candidate, the novel anti-FcγRIIB antibody BI-1206.
BI-1206 is currently being studied in two Phase 1/2 trials, in combination with rituximab in non-Hodgkin's lymphoma (NHL) and in combination with pembrolizumab in solid tumors. Latest data from the Phase 1/2 trial with BI-1206 in combination with rituximab in NHL show there are three ongoing complete responses, two beyond two years after end of treatment, and four partial responses, one of which is ongoing. The new arm of the NHL study introducing subcutaneous administration is currently recruiting patients. As anti-CD20 based therapy will remain central for the treatment of NHL, BI-1206 has the potential to be uniquely positioned within NHL.
The ongoing clinical trial with BI-1206 in solid tumors is progressing through the dose-escalation part of the trial and the two patients reported last December still show clear clinical improvement. The subcutaneous arm of the study in solid tumors is on track to be initiated in H1 2023.
'BioInvent is making strong progress with its pipeline of novel immune-modulatory antibodies to treat cancer. We now have five clinical trials in progress with four different drug candidates, underlining the strength of our proprietary technology platform. In particular, the data on our lead drug candidate BI-1206 continue to demonstrate its potential to significantly improve treatment for lymphoma and solid tumor patients. We look forward to continuing to develop BI-1206, and our other promising new treatments, to deliver on the promise of transforming the lives of cancer patients,' said Martin Welschof, CEO of BioInvent.
BioInvent is also moving several other drug candidates through clinical and preclinical development. The latest updates include:
BioInvent is hosting the R&D Day in Stockholm at 2:00 pm CET, Thursday December 8, 2022. Further details can be found on BioInvent's website www.bioinvent.com.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
Attachments
BioInvent Outlines Strong Progress in Clinical and Preclinical Pipeline at R&D Day 2022
SOURCE: BioInvent International
Get a daily dose of Seattle Bulletin news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Seattle Bulletin.
More InformationMANILA, Philippines: After a Filipina domestic worker was killed and dumped in the desert in the oil-rich emirate of Kuwait, ...
LONG BEACH, California: Long Beach, California-based Rocket Lab has launched its first mission from the United States, as part of ...
Israel was behind Sunday morning's drone strike on an Iranian munitions facility; the Wall Street Journal has reported, citing American ...
LONDON, England: Of the 14 main battle tanks and additional artillery support it will send to Ukraine, Britain hopes its ...
LONDON, England: Insurance broker Aon has estimated that natural disasters caused global economic losses worth $313 billion in 2022.It added ...
NEW YORK CITY, New York: After being convicted of stealing more than $900,000 from the company, Rosita Joseph, former executive ...
JERUSALEM, Israel: As demand for its driver-assistance technology rises among vehicle-makers, Mobileye Global is forecasting revenues for the 2023 fiscal ...
NEW YORK, New York - U.S. stocks closed sharply lower Monday as investors fretted over which way the Federal Reserve ...
Ahmedabad (Gujarat) [India], January 30 (ANI/Big News Network): The Adani group, in a sharp and focused response to Hindenburg Research's ...
SEOUL, South Korea: South Korean officials have said that the government will double energy vouchers and provide discounts on gas ...
WASHINGTON D.C.: The Wall Street Journal has reported that e-cigarette maker Juul and three tobacco giants are negotiating potential sale, ...
AUSTIN, Texas: Tesla gas announced an investment of more than $3.6 billion to expand its Nevada Gigafactory complex with the ...